Company Overview - Precision Optics Corporation, Inc. is a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, founded in 1982 [3] - The company focuses on leveraging proprietary micro-optics, 3D imaging, and digital imaging technologies to provide services from new product concept through mass manufacture [3] - Precision Optics has capabilities in in-house design, prototype, regulatory, and fabrication, enabling the design and manufacture of next-generation product solutions [3] Industry Applications - In healthcare, Precision Optics supports next-generation medical device companies by providing enhanced and smaller imaging systems for minimally invasive surgery and 3D endoscopy systems [3] - The company has supplied a variety of optical products, including complex endocouplers and specialized endoscopes, to top-tier medical device companies for decades [3] - In the defense/aerospace sector, Precision Optics applies its technical proficiency in micro-optics to meet high-quality standards while optimizing size, weight, and power [3] Upcoming Events - Precision Optics will participate in a webcasted fireside chat at the Lytham Partners 2025 Industrials & Basic Materials Investor Summit on April 1, 2025, at 3:30 p.m. ET [1][2] - The webcast can be accessed through the conference home page or directly via a specific link, with a replay available afterward [2]

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has successfully closed a public offering of 19,166,667 shares at a price of $0.30 per share, raising approximately $5.75 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The public offering consisted of common stock and pre-funded warrants, with the total gross proceeds amounting to about $5.75 million [1]. - The offering was conducted on a firm commitment basis, with WestPark Capital, Inc. serving as the Sole Book-Runner [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to fund a Phase II clinical trial for the company's lead product candidate, as well as for marketing, advertising services, working capital, and general corporate purposes [2]. Group 3: Company Background - Shuttle Pharmaceuticals, founded in 2012 by faculty members of Georgetown University Medical Center, focuses on improving outcomes for cancer patients undergoing radiation therapy [5]. - The company's mission is to enhance the effectiveness of radiation therapy while minimizing side effects, aiming to increase cancer cure rates and improve patient quality of life [5].

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has announced a public offering of 19,166,667 shares at a price of $0.30 per share, aiming to raise approximately $5.75 million to fund its Phase II clinical trial and other corporate purposes [1][2]. Group 1: Offering Details - The public offering is priced at $0.30 per share, with expected gross proceeds of about $5.75 million before expenses [1]. - The offering is set to close on March 13, 2025, pending customary closing conditions [1]. - WestPark Capital, Inc. is acting as the Sole Book-Runner for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to fund the Phase II clinical trial for the lead product candidate, marketing and advertising services, and general corporate purposes [2]. Group 3: Company Overview - Shuttle Pharmaceuticals, founded in 2012, focuses on improving outcomes for cancer patients undergoing radiation therapy by developing therapies that enhance the effectiveness of radiation while minimizing side effects [5]. - The company aims to increase cancer cure rates and improve patient quality of life through the development of radiation sensitizers [5].